ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Share price
−$22.23 (−23.45%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ANI PHARMACEUTICALS INC grew revenue 30.9% to $978.38M over the twelve months to Jun 30, 2026. Operating income rose 889.9% to $150.36M, moving the operating margin from 2.0% to 15.4%. Free cash flow was $172.99M, up 37.9% from a year earlier.
Revenue
$978.38M
+30.9% vs. a year earlier
Operating income
$150.36M
+889.9% vs. a year earlier
Free cash flow
$172.99M
+37.9% vs. a year earlier
EPS, diluted
$4.70
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.59B
- P/E ratio
- 15.4
- Price to sales
- 1.63
- Price to book
- 2.66
- Dividend yield
- –
- Free cash flow yield
- 10.88%
Fundamentals
- Revenue
- $978.38M
- Net income
- $108.31M
- EPS, diluted
- $4.70
- Free cash flow
- $172.99M
- Book value per share
- $27.25
- Diluted shares
- 22M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$978.38M+30.9% YoY
Gross profit
$590.98M+29.5% YoY
Operating income
$150.36M+889.9% YoY
Net income
$108.31M
EPS, diluted
$4.70
Free cash flow
$172.99M+37.9% YoY
Reported periodTrailing twelve months